James R. Tobin - 14 May 2025 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
16 May 2025, 16:30:42 UTC
Prior SEC filing
28 Mar 2025
Next SEC filing
23 May 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jason Cavalier, Attorney-in-Fact for James R. Tobin

Key filing fact

James R. Tobin filed Form 4 for Lyra Therapeutics, Inc. (LYRA) on 16 May 2025.

Key facts

  • This page summarizes James R. Tobin's Form 4 filing for Lyra Therapeutics, Inc. (LYRA).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 16 May 2025, 16:30.

Change

  • Previous filing in this sequence was filed on 28 Mar 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001190128 Primary reporting owner

TOBIN JAMES R

Relationship
Director
Address
C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN
Signature
/s/ Jason Cavalier, Attorney-in-Fact for James R. Tobin
Signature date
16 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LYRA transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+32,000
Change %
Price
$0.000000
Shares after
32,000
Date
14 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
32,000
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .